Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study

被引：6

作者：

Santoni, Matteo ^{[1
]}

Massari, Francesco ^{[2
]}

Grande, Enrique ^{[3
]}

Procopio, Giuseppe ^{[4
]}

Matrana, Marc R. ^{[5
]}

Rizzo, Mimma ^{[6
]}

De Giorgi, Ugo ^{[7
]}

Basso, Umberto ^{[8
]}

Milella, Michele ^{[9
]}

Iacovelli, Roberto ^{[10
]}

Aurilio, Gaetano ^{[11
]}

Incorvaia, Lorena ^{[12
]}

Buti, Sebastiano ^{[13
]}

Caffo, Orazio ^{[14
]}

Fornarini, Giuseppe ^{[15
]}

Carrozza, Francesco ^{[16
]}

Mollica, Veronica ^{[2
]}

Rizzo, Alessandro ^{[2
]}

Farag, Fady ^{[5
]}

Molina-Cerrillo, Javier ^{[17
]}

Battelli, Nicola ^{[1
]}

机构：

[1] Macerata Hosp, Oncol Unit, Macerata, Italy

[2] IRCCS Azienda Osped Univ Bologna, Med Oncol, Bologna, Italy

[3] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[4] Ist Nazl Tumori IRCCS, Dept Med Oncol, Milan, Italy

[5] Ochsner Med Ctr, Dept Internal Med, Hematol Oncol, New Orleans, LA USA

[6] RCCS San Matteo Univ Hosp Fdn, Med Oncol, Pavia, Italy

[7] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy

[8] Ist Oncol Veneto IOV IRCCS, Dept Med Oncol, Padua, Italy

[9] Azienda Osped Univ Integrata, Univ & Hosp Trust Verona, UOC Oncol, Verona, Italy

[10] Fdn Policlin Univ A Gemelli IRCCS, Med Oncol, Rome, Italy

[11] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy

[12] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[13] Univ Hosp Parma, Med Oncol Unit, Parma, Italy

[14] Santa Chiara Hosp, Med Oncol Dept, Trento, Italy

[15] IRCCS Osped Policlin San Martino, Med Oncol Unit 1, Genoa, Italy

[16] City Hosp, Oncol Unit, Faenza, Italy

[17] Hosp Ramon & Cajal, Dept MedicalOncol, Madrid, Spain

来源：

TARGETED ONCOLOGY | 2021年 / 16卷 / 05期

关键词：

MESENCHYMAL TRANSITION;

D O I：

10.1007/s11523-021-00828-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Renal cell carcinoma with sarcomatoid differentiation is a highly aggressive form of kidney cancer. Objective We aimed to analyze the outcomes of patients treated with cabozantinib for metastatic renal cell carcinoma with sarcomatoid features. Methods We retrospectively collected data from 16 worldwide centers. Overall survival and progression-free survival were analyzed using Kaplan-Meier curves. Cox proportional models were used for univariate and multivariate analyses. Results We collected data from 66 patients with metastatic sarcomatoid renal cell carcinoma receiving cabozantinib as second-line (51%) or third-line (49%) therapy. The median progression-free survival from the start of cabozantinib was 7.59 months (95% confidence interval [CI] 5.75-17.49) and was longer in male patients (8.81 vs 5.95 months, p = 0.042) and in patients without bone metastases (7.59 vs 5.11 months, p = 0.010); the median overall survival was 9.11 months (95% CI 7.13-23.80). At the multivariate analysis, female sex (hazard ratio = 1.81; 95% CI 1.02-3.37, p = 0.046), bone metastases (hazard ratio = 2.62; 95% CI 1.34-5.10, p = 0.005), and International Metastatic Renal Cell Carcinoma Database Consortium criteria (hazard ratio = 3.04; 95% CI 1.54-5.99, p = 0.001) were significant predictors of worse overall survival. Conclusions Our data show that cabozantinib is active in pretreated patients with sarcomatoid renal cell carcinoma. Biomarkers are needed in this field to select patients for multi-kinase inhibitors or other options.

引用

页码：625 / 632

页数：8

共 50 条

[1] Cabozantinib in Pretreated Patients with Metastatic Renal Cell Carcinoma with Sarcomatoid Differentiation: A Real-World Study
Matteo Santoni
Francesco Massari
Enrique Grande
Giuseppe Procopio
Marc R. Matrana
Mimma Rizzo
Ugo De Giorgi
Umberto Basso
Michele Milella
Roberto Iacovelli
Gaetano Aurilio
Lorena Incorvaia
Sebastiano Buti
Orazio Caffo
Giuseppe Fornarini
Francesco Carrozza
Veronica Mollica
Alessandro Rizzo
Fady Farag
Javier Molina-Cerrillo
Nicola Battelli
Targeted Oncology, 2021, 16 : 625 - 632
[2] Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study
Flechon, A.
Chevreau, C. M.
Topart, D.
Gravis, G.
Oudard, S.
Tourani, J. M.
Geoffrois, L.
Meriaux, E.
Thiery-Vuillemin, A.
Barthelemy, P.
Ladoire, S.
Laguerre, B.
Bourouina, R.
Perrot, V.
Escudier, B.
Gross-Goupil, M.
Albiges, L.
ANNALS OF ONCOLOGY, 2020, 31 : S572 - S573
[3] Real-world experience with cabozantinib in metastatic clear cell renal cell carcinoma (mccRCC).
Lemke, Emily
Shah, Amishi Yogesh
Chandramohan, Anuradha
Campbell, Matthew T.
VanAlstine, Michael
Jonasch, Eric
Tannir, Nizar M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[4] Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma
Bruchbacher, Andreas
Franke, Johannes
Alimohammadi, Arman
Laukhtina, Ekaterina
Fajkovic, Harun
Schmidinger, Manuela
CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 98 - 108
[5] Effects of cabozantinib on bone turnover markers in real-world metastatic renal cell carcinoma
Ratta, Raffaele
Verzoni, Elena
Mennitto, Alessia
Pantano, Francesco
Martinetti, Antonia
Raimondi, Alessandra
Sepe, Pierangela
Sottotetti, Elisa
Mennitto, Roberta
Morelli, Daniele
Santini, Daniele
de Braud, Filippo G.
Procopio, Giuseppe
TUMORI JOURNAL, 2021, 107 (06): : 542 - 549
[6] Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Tsai, Y-C.
Li, J-R.
Su, P. J.
Su, Y-L.
Chung, H-J.
Li, C-C.
Huang, C-P.
Guo, J-C.
Chen, C-S.
Wang, E.
Perrot, V.
Chang, Y. H.
ANNALS OF ONCOLOGY, 2022, 33 : S1487 - S1488
[7] Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients
Iacovelli, Roberto
Ciccarese, Chiara
Fornarini, Giuseppe
Massari, Francesco
Bimbatti, Davide
Mosillo, Claudia
Rebuzzi, Sara Elena
Di Nunno, Vincenzo
Grassi, Massimiliano
Fantinel, Emanuela
Ardizzoni, Andrea
Tortora, Giampaolo
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (06) : 1283 - 1289
[8] Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium
Stukalin, I
Wells, J. C.
Graham, J.
Yuasa, T.
Beuselinck, B.
Kollmansberger, C.
Ernst, D. S.
Agarwal, N.
Le, T.
Donskov, F.
Hansen, A. R.
Bjarnason, G. A.
Srinivas, S.
Wood, L. A.
Alva, A. S.
Kanesvaran, R.
Fu, S. Y. F.
Davis, I. D.
Choueiri, T. K.
Heng, D. Y. C.
CURRENT ONCOLOGY, 2019, 26 (02) : E175 - E179
[9] CLINICAL OUTCOMES OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH OR WITHOUT SARCOMATOID DIFFERENTIATION TREATED WITH SYSTEMIC THERAPY IN REAL-WORLD CANADIAN SETTING
Bou-Nehme, Sawaya G.
Dragomir, A.
Kollmannsberger, C.
Basappa, N. S.
Kapoor, A.
Soulieres, D.
Finelli, A.
Heng, D. Y. C.
Wood, L.
Castonguay, V
Canil, C.
Winquist, E.
Graham, J.
Bjarnason, G. A.
Bhindi, B.
Lalani, A. K.
Pouliot, F.
Breau, R. H.
Tanguay, S.
VALUE IN HEALTH, 2022, 25 (12) : S39 - S39
[10] Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
Janisch, Florian
Kienapfel, Christina
Fuehner, Constantin
Klotzbuecher, Thomas
Marks, Phillip
Hillemacher, Tobias
Meyer, Christian P.
Iwata, Takehiro
Parizi, Mehdi Kardoust
Sauter, Guido
Fisch, Margit
Shariat, Shahrokh F.
Dahlem, Roland
Rink, Michael
FRONTIERS IN SURGERY, 2021, 8

← 1 2 3 4 5 →